Exobiosphere joins Cedars-Sinai Accelerator with $1.4m

As part of this, Cedars-Sinai Technology Ventures is making a strategic investment of $1.4 million in the company.

The funding will accelerate the development of Exobiosphere's Orbital High-Throughput Screener (OHTS). This autonomous laboratory platform is designed to conduct thousands of biological tests in microgravity, aiming to advance drug discovery by leveraging the unique environment of space.

Joining the Cedars-Sinai Accelerator+ is a transformational milestone for Exobiosphere. This partnership allows us to validate our technology with world-class health professionals and accelerate the commercialization of orbital biology at scale.

Kyle Acierno, CEO and Co-Founder

Over the next year, the Exobiosphere team will collaborate with physicians and researchers at Cedars-Sinai Medical Center in Los Angeles. This partnership will help refine the technology and prepare for sending biological samples into orbit.

Working alongside Cedars-Sinai’s translational ecosystem lets us see where patient care truly meets its limits, and use space as a new frontier to overcome them.

Dr. Bruno Santos, Co-Founder and Director of R&D

This achievement follows a recent $2.3 million seed round and a LuxIMPULSE grant from the Luxembourg Space Agency, reinforcing the company's mission to improve health on Earth through orbital biotechnology.